Shelly Wang, PhD (she/her/hers)

Principal Scientist II
Gilead Sciences, United States

Shelly Wang, Ph.D, is a Principal Scientist II in Clinical Pharmacology Sciences at Gilead. She earned her PhD degree in Biomedical Engineering from the University of Southern California. She has over 16 years of pharmaceutical industry experience in clinical drug development and the area of pharmacometrics. Her knowledge and expertise include quantitative clinical pharmacology in oncology, immuno-science and pediatrics. She joined Gilead Sciences in 2024 and currently leads the pharmacometric strategy for the oncology and immunology therapeutic areas.

Disclosure(s): Gilead Sciences: Employment (Ongoing); Metrum Research Group: Employment (Terminated)

Presentation(s):

• Standardization and Best Practices as Bridges to the Future: Securing the Foundation for Growth of Model-Informed Drug Development

  Monday, November 11, 2024
  12:30 PM – 2:00 PM MST

• Quantitative clinical pharmacology of antibody drug conjugate development: challenges and opportunities

  Wednesday, November 13, 2024
  1:45 PM – 3:15 PM MST